Last edition
News about "TABRECTA "
US FDA Accepts Tabelecleucel BLA Resubmission for EBV-PTLD
The US FDA has accepted Pierre Fabre’s tabelecleucel BLA resubmission for EBV-positive PTLD, with a target decision date of March 31, 2027.
Tabrecta | 15/10/2026 | By News Bureau
Natco Pharma Submits ANDA for Generic Version of TABRECTA
Natco claims to be the first company to have filed a substantially complete ANDA containing a paragraph IV certification for this product and expects to be eligible for 180 days of sole marketing exclusivity at the time of the potential launch of the product under certain circumstances.
TABRECTA | 31/08/2024 | By Aishwarya | 966
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy